In April 2007, the United States Patent and Trademark Office (the “USPTO”) issued to the Company U.S. Patent No. 7,201,920 titled ”Methods and Compositions for Deterring Abuse of Opioid Containing Dosage Forms”.   The 54 allowed patent claims encompass  pharmaceutical compositions intended to reduce or discourage the three most common methods of prescription opioid analgesic product misuse and abuse (the Company's "Aversion® Technology") including; (i) intravenous injection of dissolved tablets or capsules; (ii) snorting of crushed tablets or capsules and; (iii) intentionally swallowing excess quantities of tablets or capsules.  The opioid analgesics in the issued patent claims include oxycodone, hydrocodone, hydromorphone, morphine, codeine, tramadol, propoxyphene and many others.  

In addition to issued U.S. Patent No. 7,201,920, the Company has pending five U.S. non-provisional patent applications, three WO/PCT patent applications and multiple additional U.S. provisional and international patent filings relating to compositions containing abuseable drugs.

At present, except for the rights conferred in the King Agreement, the Company retains ownership of all intellectual property and commercial rights to its Aversion® Technology and related product candidates.